Astrazeneca Pharma India Share Price
Sector: Major Drugs
8900.00 +171.55 (1.97%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
8651.00
Today’s High
8900.00
52 Week Low
5000.00
52 Week High
9199.00
8840.00 +115.00 (1.32%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
8650.50
Today’s High
8916.00
52 Week Low
4800.15
52 Week High
9211.00
Key Metrics
- Market Cap (In Cr) 22219.46
- Beta 0.38
- Div. Yield (%) 0.28
- P/B 30.64
- TTM P/E 188.36
- Peg Ratio 11.21
- Sector P/E 26.62
- Open Price 8651
- Prev Close 8728.45
Astrazeneca Pharma India Analysis
Price Analysis
-
1 Week-0.24%
-
3 Months25.93%
-
6 Month22.16%
-
YTD19.44%
-
1 Year63.63%
Risk Meter
- 40% Low risk
- 40% Moderate risk
- 40% Balanced Risk
- 40% High risk
- 40% Extreme risk
Astrazeneca Pharma India News
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy
1 min read . 05 Mar 2025Stocks to Watch: Adani Group stocks, IRCTC, Vodafone, IRCON, Vedanta, and more
5 min read . 12 Feb 2025Stocks to Watch: Reliance Power, SpiceJet, Vodafone Idea, NHPC, PNB, and more
2 min read . 24 Sep 2024Astrazeneca Pharma India Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 1295.53
- Selling/ General/ Admin Expenses Total
- 418.96
- Depreciation/ Amortization
- 14.94
- Other Operating Expenses Total
- 12.07
- Total Operating Expense
- 1108.91
- Operating Income
- 186.62
- Net Income Before Taxes
- 219.54
- Net Income
- 161.51
- Diluted Normalized EPS
- 60.13
- Period
- 2024
- Total Assets
- 1078.03
- Total Liabilities
- 366.11
- Total Equity
- 711.92
- Tangible Book Valueper Share Common Eq
- 283.92
- Period
- 2024
- Cashfrom Operating Activities
- 27.87
- Cashfrom Investing Activities
- 21.74
- Cashfrom Financing Activities
- -44.38
- Net Changein Cash
- 5.23
- Period
- 2023
- Total Revenue
- 1002.97
- Selling/ General/ Admin Expenses Total
- 397.16
- Depreciation/ Amortization
- 16.26
- Other Operating Expenses Total
- 9.89
- Total Operating Expense
- 894.34
- Operating Income
- 108.63
- Net Income Before Taxes
- 134.1
- Net Income
- 99.29
- Diluted Normalized EPS
- 50.89
- Period
- 2023
- Total Assets
- 984.87
- Total Liabilities
- 396.18
- Total Equity
- 588.69
- Tangible Book Valueper Share Common Eq
- 235.48
- Period
- 2023
- Cashfrom Operating Activities
- 58.29
- Cashfrom Investing Activities
- 18.11
- Cashfrom Financing Activities
- -24.48
- Net Changein Cash
- 51.92
- Period
- 2022
- Total Revenue
- 805.6
- Selling/ General/ Admin Expenses Total
- 343.64
- Depreciation/ Amortization
- 16.95
- Other Operating Expenses Total
- 10.09
- Total Operating Expense
- 736.24
- Operating Income
- 69.36
- Net Income Before Taxes
- 83.04
- Net Income
- 61.6
- Diluted Normalized EPS
- 23.8
- Period
- 2022
- Total Assets
- 856.56
- Total Liabilities
- 345.17
- Total Equity
- 511.39
- Tangible Book Valueper Share Common Eq
- 204.56
- Period
- 2022
- Cashfrom Operating Activities
- 100.8
- Cashfrom Investing Activities
- 4.74
- Cashfrom Financing Activities
- -9.46
- Net Changein Cash
- 96.08
- Period
- 2021
- Total Revenue
- 813.56
- Selling/ General/ Admin Expenses Total
- 326.58
- Depreciation/ Amortization
- 20.13
- Other Operating Expenses Total
- 13.06
- Total Operating Expense
- 697.68
- Operating Income
- 115.88
- Net Income Before Taxes
- 127.09
- Net Income
- 93.3
- Diluted Normalized EPS
- 36.68
- Period
- 2021
- Total Assets
- 774.71
- Total Liabilities
- 318.54
- Total Equity
- 456.17
- Tangible Book Valueper Share Common Eq
- 182.47
- Period
- 2021
- Cashfrom Operating Activities
- 104.78
- Cashfrom Investing Activities
- 173.03
- Cashfrom Financing Activities
- -8.97
- Net Changein Cash
- 268.84
- Period
- 2020
- Total Revenue
- 831.81
- Selling/ General/ Admin Expenses Total
- 356.29
- Depreciation/ Amortization
- 18.58
- Other Operating Expenses Total
- 12.29
- Total Operating Expense
- 729.25
- Operating Income
- 102.56
- Net Income Before Taxes
- 113.97
- Net Income
- 72.21
- Diluted Normalized EPS
- 28.81
- Period
- 2020
- Total Assets
- 706.36
- Total Liabilities
- 341.92
- Total Equity
- 364.44
- Tangible Book Valueper Share Common Eq
- 145.78
- Period
- 2020
- Cashfrom Operating Activities
- 87.42
- Cashfrom Investing Activities
- -170.8
- Cashfrom Financing Activities
- -6.36
- Net Changein Cash
- -89.74
- Period
- 2019
- Total Revenue
- 728.29
- Selling/ General/ Admin Expenses Total
- 370.35
- Depreciation/ Amortization
- 14.92
- Other Operating Expenses Total
- 8.55
- Total Operating Expense
- 671.72
- Operating Income
- 56.57
- Net Income Before Taxes
- 72.67
- Net Income
- 54.45
- Diluted Normalized EPS
- 21.76
- Period
- 2019
- Total Assets
- 561.8
- Total Liabilities
- 261
- Total Equity
- 300.8
- Tangible Book Valueper Share Common Eq
- 120.32
- Period
- 2019
- Cashfrom Operating Activities
- 54.98
- Cashfrom Investing Activities
- 4.28
- Net Changein Cash
- 59.26
- Period
- 2018
- Total Revenue
- 571.99
- Selling/ General/ Admin Expenses Total
- 283.94
- Depreciation/ Amortization
- 14.74
- Other Operating Expenses Total
- 5.93
- Total Operating Expense
- 539.69
- Operating Income
- 32.3
- Net Income Before Taxes
- 43.8
- Net Income
- 25.91
- Diluted Normalized EPS
- 10.89
- Period
- 2018
- Total Assets
- 460.54
- Total Liabilities
- 213.61
- Total Equity
- 246.93
- Tangible Book Valueper Share Common Eq
- 98.77
- Period
- 2018
- Cashfrom Operating Activities
- 8.79
- Cashfrom Investing Activities
- -9.36
- Net Changein Cash
- -0.57
- Period
- 2024-12-31
- Total Revenue
- 440.29
- Selling/ General/ Admin Expenses Total
- 84.94
- Depreciation/ Amortization
- 9.07
- Other Operating Expenses Total
- 31.33
- Total Operating Expense
- 405.92
- Operating Income
- 34.37
- Net Income Before Taxes
- 42.02
- Net Income
- 30.85
- Diluted Normalized EPS
- 22.19
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 408
- Selling/ General/ Admin Expenses Total
- 92.57
- Depreciation/ Amortization
- 9.32
- Other Operating Expenses Total
- 36.98
- Total Operating Expense
- 364.8
- Operating Income
- 43.2
- Net Income Before Taxes
- 51.03
- Net Income
- 38.43
- Diluted Normalized EPS
- 15.37
- Period
- 2024-09-30
- Total Assets
- 1241.3
- Total Liabilities
- 561.95
- Total Equity
- 679.35
- Tangible Book Valueper Share Common Eq
- 270.98
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 38.45
- Cashfrom Investing Activities
- 15.7
- Cashfrom Financing Activities
- -63.2
- Net Changein Cash
- -9.05
- Period
- 2024-06-30
- Total Revenue
- 387.52
- Selling/ General/ Admin Expenses Total
- 78.31
- Depreciation/ Amortization
- 3.91
- Other Operating Expenses Total
- 40.7
- Total Operating Expense
- 410.92
- Operating Income
- -23.4
- Net Income Before Taxes
- -15.16
- Net Income
- -11.79
- Diluted Normalized EPS
- 10.26
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 383.2
- Selling/ General/ Admin Expenses Total
- 83.3
- Depreciation/ Amortization
- 3.76
- Other Operating Expenses Total
- 36.96
- Total Operating Expense
- 337.57
- Operating Income
- 45.63
- Net Income Before Taxes
- 54.36
- Net Income
- 39.48
- Diluted Normalized EPS
- 15.79
- Period
- 2024-03-31
- Total Assets
- 1078.03
- Total Liabilities
- 366.11
- Total Equity
- 711.92
- Tangible Book Valueper Share Common Eq
- 283.92
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 27.87
- Cashfrom Investing Activities
- 21.74
- Cashfrom Financing Activities
- -44.38
- Net Changein Cash
- 5.23
- Period
- 2023-12-31
- Total Revenue
- 305.79
- Selling/ General/ Admin Expenses Total
- 91.56
- Depreciation/ Amortization
- 3.7
- Other Operating Expenses Total
- 50.89
- Total Operating Expense
- 294.44
- Operating Income
- 11.35
- Net Income Before Taxes
- 20.4
- Net Income
- 15.8
- Diluted Normalized EPS
- 6.32
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 311.07
- Selling/ General/ Admin Expenses Total
- 82.02
- Depreciation/ Amortization
- 3.67
- Other Operating Expenses Total
- 54.16
- Total Operating Expense
- 245.56
- Operating Income
- 65.51
- Net Income Before Taxes
- 73.38
- Net Income
- 52.37
- Diluted Normalized EPS
- 16.26
- Period
- 2023-09-30
- Total Assets
- 1101.55
- Total Liabilities
- 446.59
- Total Equity
- 654.97
- Tangible Book Valueper Share Common Eq
- 261.99
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 49.45
- Cashfrom Investing Activities
- 12.51
- Cashfrom Financing Activities
- -42.18
- Net Changein Cash
- 19.78
- Period
- 2023-06-30
- Total Revenue
- 295.47
- Selling/ General/ Admin Expenses Total
- 76.02
- Depreciation/ Amortization
- 3.8
- Other Operating Expenses Total
- 41.62
- Total Operating Expense
- 232.02
- Operating Income
- 63.45
- Net Income Before Taxes
- 71.4
- Net Income
- 53.86
- Diluted Normalized EPS
- 21.54
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 284.7
- Selling/ General/ Admin Expenses Total
- 81.06
- Depreciation/ Amortization
- 4.25
- Other Operating Expenses Total
- 45.17
- Total Operating Expense
- 269.34
- Operating Income
- 15.36
- Net Income Before Taxes
- 23.28
- Net Income
- 17.27
- Diluted Normalized EPS
- 18.84
- Period
- 2023-03-31
- Total Assets
- 984.87
- Total Liabilities
- 396.18
- Total Equity
- 588.69
- Tangible Book Valueper Share Common Eq
- 235.48
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 58.29
- Cashfrom Investing Activities
- 18.11
- Cashfrom Financing Activities
- -24.48
- Net Changein Cash
- 51.92
- Period
- 2022-12-31
- Total Revenue
- 249.81
- Selling/ General/ Admin Expenses Total
- 83.93
- Depreciation/ Amortization
- 4.13
- Other Operating Expenses Total
- 37.82
- Total Operating Expense
- 217.35
- Operating Income
- 32.46
- Net Income Before Taxes
- 39.46
- Net Income
- 29.3
- Diluted Normalized EPS
- 11.72
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Astrazeneca Pharma India Technical
Moving Average
SMA
- 5 Day8886.46
- 10 Day8707.06
- 20 Day8342.31
- 50 Day7700.29
- 100 Day7222.22
- 300 Day7137.77
Astrazeneca Pharma India Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Aurobindo Pharma
- 1246.75
- 28.9
- 2.37
- 1592.55
- 994.35
- 72599.23
- Astrazeneca Pharma India
- 8900
- 171.55
- 1.97
- 9199
- 5000
- 22219.46
- Pfizer
- 4267.9
- 21.8
- 0.51
- 6452.85
- 3742.9
- 19526.05
- Neuland Laboratories
- 12570.65
- 270.05
- 2.2
- 18089.55
- 5557
- 16064.79
- Unichem Laboratories
- 616.1
- -3.5
- -0.56
- 949.85
- 507.2
- 4379.4
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Aurobindo Pharma
- 21.4
- 2.4
- 14.22
- 12.72
- Astrazeneca Pharma India
- 145.11
- 30.64
- 20.1
- 10.27
- Pfizer
- 35.49
- 5.41
- 18.43
- 24.05
- Neuland Laboratories
- 49.57
- 12.3
- 14.98
- 11.99
- Unichem Laboratories
- -
- 1.84
- -2.1
- -3.99
Astrazeneca Pharma India Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 11-Feb-25
- Quarterly Results
- 13-Nov-24
- Quarterly Results
- 08-Aug-24
- Quarterly Results
- 27-May-24
- Audited Results & Dividend
- 08-Feb-24
- Quarterly Results
- 09-Nov-23
- Quarterly Results
- 14-Aug-23
- Quarterly Results
- 30-May-23
- Audited Results & Dividend
- 10-Feb-23
- Quarterly Results
- 11-Nov-22
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 29-Mar-25
- 24-Feb-25
- POM
- 24-Dec-24
- 22-Nov-24
- POM
- 08-Aug-24
- 16-Jul-24
- AGM
- 07-Apr-24
- 06-Mar-24
- POM
- 08-Feb-24
- 05-Jan-24
- POM
- 14-Aug-23
- 30-May-23
- AGM
- 27-Feb-23
- 25-Jan-23
- POM
- 08-Aug-22
- 26-May-22
- AGM
- 31-Mar-22
- 23-Feb-22
- POM
- 09-Aug-21
- 26-May-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 27-May-24
- 05-Jul-24
- 05-Jul-24
- 24
- 30-May-23
- 14-Jul-23
- 14-Jul-23
- 16
- 26-May-22
- 08-Jul-22
- 07-Jul-22
- 8
- 09-Aug-21
- 20-Aug-21
- 18-Aug-21
- 2


